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Plasma proGRP Concentration is Sensitive and Specific for 
Discriminating Small Cell Lung Cancer from Nonmalignant 
Conditions or Non-small Cell Lung Cancer
To date, most clinical data on pro-gastrin-releasing peptide (proGRP) have been based on 
serum concentrations. This study evaluated the agreement between proGRP levels in fresh 
serum and plasma in patients with various lung diseases. Pairs of serum and EDTA plasma 
were collected from 49 healthy individuals. At the same time, EDTA plasma of 118 lung 
cancer patients and 23 patients with benign pulmonary diseases were prospectively 
collected. Compared to serum, plasma proGRP concentrations were higher by an average 
of 103.3%. Plasma proGRP was higher in malignancy (336.4 ± 925.4 pg/mL) than in 
benign conditions (40.1 ± 11.5 pg/mL). Small cell lung cancer (SCLC) patients showed 
higher levels of proGRP (1,256.3 ± 1,605.6 pg/mL) compared to other types of lung 
cancer. Based on the ROC curve analyses at a specificity of 95%, the diagnostic sensitivity 
of plasma proGRP was estimated to be 83.8% in distinguishing SCLC from all the other 
conditions, and 86.5% for discriminating SCLC from the nonmalignant cases. Among the 
SCLC cases, limited stage disease had lower levels of plasma proGRP than extensive disease. 
When measuring circulating levels of proGRP, the use of plasma is preferred over serum. 
Plasma proGRP has a potential marker for discriminating SCLC from nonmalignant 
conditions or non-small cell lung cancer.
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ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION
Lung cancer is the most common fatal cancer worldwide and 
has become the leading cause of cancer deaths in Korea. The 
number of new cases will continue to rise. The risk of human 
cancer can be associated with environmental, occupational, 
and recreational exposures to carcinogens (1). Pro-gastrin-re-
leasing peptide (proGRP, residues 31-98) is a precursor of a neu-
ropeptide hormone named gastrin-releasing peptide (GRP), 
and is frequently produced by small cell lung cancer (SCLC) 
cells (2, 3). Circulating proGRP levels have been shown to serve 
as a reliable marker in SCLC patients (4-6). ProGRP has been 
reported to be the most sensitive marker for discriminating SCLC 
from benign diseases of the lung (7). If measured with serum 
neuron-specific enolase at the same time, proGRP is known to 
provide additive information on pathological characteristics of 
lung cancer (5, 8-10). Moreover, proGRP was found to be useful 
in the monitoring of response to therapy and for the detection 
of recurrent SCLC (8, 10, 11). 
  ProGRP is significantly more stable in blood than GRP. How-
ever, the stability of ProGRP in serum is worse than the stability 
of other widely used serum cancer markers, such as carcino-
embryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 
19-9) (12, 13). The relative instability of ProGRP in serum is be-
lieved to be caused by thrombin, which is generated during the 
clotting process (14). By using EDTA-anticoagulated plasma 
specimens, the stability of proGRP can be improved especially 
at room temperature. However, there are different views wheth-
er proGRP concentrations of fresh serum differ from that of fresh 
EDTA plasma, and which matrix is preferred (14, 15). Moreover, 
there is little clinical information currently available about the 
use of plasma proGRP in patient populations, since major clini-Kim H-R, et al.  •  proGRP Level in Different Types of Specimens and Lung Cancer 
626   http://jkms.org DOI: 10.3346/jkms.2011.26.5.625
cal investigations on proGRP have used almost exclusively se-
rum specimens (2, 6, 9, 16). 
  The objectives of this study were to evaluate the difference of 
proGRP concentrations in serum and plasma using fresh speci-
mens, and to investigate plasma proGRP concentrations in be-
nign and malignant conditions including SCLC. 
MATERIALS AND METHODS
Samples  
Pairs of serum and EDTA plasma specimens from each of the 
healthy 27 males and 22 females were collected. The ages of the 
healthy individuals ranged from 45 to 83 yr with a mean of 62.1 
yr. The analyses of the specimens were completed within 4 hr 
from the time the samples were collected.
  During a 9 month period starting from January 2009, EDTA 
plasma specimens were obtained in a consecutive manner from 
patients who were newly diagnosed with lung diseases during 
their first visit to a pulmonology clinic at a tertiary teaching hos-
pital (n = 178). Ages ranged from 39 to 97 yr with a mean of 65.2 yr. 
Among the patients, 137 (77.0%) were male. From each patient, 
an EDTA plasma specimen was separated by immediate centrif-
ugation and was stored at -20°C until the proGRP assay was per-
formed. Within the patient population, l55 were later diagnosed 
with lung cancer and 23 were diagnosed with benign pulmonary 
diseases.  
  All cases of lung cancer were diagnosed histologically and 
staged with the TNM system. Of the non-small cell lung cancer 
(NSCLC) patients, 16.4% were in stage I or II, 32.7% were in stage 
III, and 50.9% were in stage IV. Of the SCLC patients, 48.4% were 
in limited stage and 51.6% were in extensive stage (Table 1). 
Measurement of the tumor marker concentrations
All blood collection tubes were from BD Vacutainer (BD Vacu-
tainer Systems, Plymouth, UK). For all the serum and plasma 
specimens, proGRP concentrations were measured using a ful-
ly automated immunoassay, the ARCHITECT ProGRP (Abbott 
Laboratories, Wiesbaden, Germany) assay. The ARCHITECT 
ProGRP assay was a two-step chemiluminescent immunoas-
say. In the first step, sample, assay diluent, and anti-proGRP 
coated paramagnetic microparticles were combined. ProGRP 
present in the sample binded to the anti-proGRP coated mic-
roparticles. After washing, anti-proGRP acridinium-labeled con-
jugate was added to create a reaction mixture in the second step. 
Following another wash, pre-trigger and trigger solutions were 
added to the reaction mixture. The resulting chemiluminescent 
reaction was measured as relative light units. A direct relation-
ship existed between the amount of proGRP in the sample and 
the relative light units detected. 
  Concentrations of squamous cell carcinoma antigen (SCC) 
and neuron-specific enolase (NSE) were compared between 
serum and plasma obtained from the healthy individuals. The 
ARCHITECT SCC reagent and the Modular NSE reagent (Roche 
Diagnostics GmbH, Mannheim, Germany) were employed for 
measuring the respective analyte. The ARCHITECT SCC assay 
was a two-step chemiluminescent immunoassay. In the first step, 
sample and anti-SCC coated paramagnetic microparticles were 
combined. SCC present in the sample binded to the anti-SCC 
coated microparticles. After washing, anti-SCC acridinium-la-
beled conjugate was added to create a reaction mixture in the 
second step. The later part of the procedure was identical to that 
of the ARCHITECT ProGRP assay. The Modular NSE assay was 
a chemiluminescent immunoassay. At first, NSE present in the 
sample, biotinylated anti-NSE and anti-NSE labeled with ruthe-
nium complex form a sandwich complex. After addition of strep-
tavidin coated microparticles, the complex became bound to the 
solid phase via interaction of biotin and streptavidin. In the mea-
suring cell, microparticles were magnetically onto the surface of 
the electrode. Application of a voltage to the electrode then in-
duced chemiluminescent emission which was measured by a 
photomultiplier. Results were determined via a calibration curve.
  According to the manufacturers, both serum and plasma could 
Table 1. Clinical characteristics of the patients with lung diseases
Lung diseases
Number  
(male/female)
Age (yr)
Disease stage (number)
Limited Extensive
Malignant diseases
   Small cell lung caner  37 (29/8) 65.6 (48-85) 18 19
I II III IV Unstaged
   Non-small cell lung cancer 116 (94/22) 64.9 (44-79) 15 6 37 53 5
      Squamous cell carcinoma 59 (56/3) 64.7 (46-79)   6 5 26 19 3
      Adenocarcinoma   40 (22/18) 64.5 (44-77)   8   8 23 1
      Large cell cancer  5 (4/1) 68.3 (63-75) 1   4
      Unspecified non-small cell cancer 12 (12/0) 65.6 (45-77)   1  3   7 1
   Secondary lung cancer*  2 (1/1) 59.5 (49-70)
Benign lung diseases
†   23 (13/10) 60.8 (44-80)
*One case was metastasized from rectal cancer and the other was from esophageal cancer; 
†Specific diagnoses were pulmonary tuberculosis (n = 7), pneumonia (n = 5), 
mycobacterial infection other than tuberculosis (n = 2), a solitary benign nodule (n = 2), nontuberculous granuloma (n = 2), a case each of parasitic infection, paraganglioma, 
hamartoma, eosinophilic infiltration and idiopathic pulmonary fibrosis.Kim H-R, et al.  •  proGRP Level in Different Types of Specimens and Lung Cancer 
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be used for measuring SCC concentrations, whereas plasma 
specimens were not allowed to be used with the Modular NSE 
reagent. 
Statistical analysis
Statistical analyses were conducted using MedCalc 9.5.2 (Med-
Calc Software, Mariakerke, Belgium) with the significance level 
of 0.05. The median and range of proGRP, SCC and NSE were 
calculated for the healthy individual’s serum and plasma. The 
median and range of plasma proGRP were calculated separate-
ly for the healthy individuals, benign lung diseases and lung 
cancer. These values were also calculated by histology and stage 
of the lung cancer cases. The Wilcoxon-rank sum test or Krus-
kal-Wallis test was used to determine if there was a statistically 
significant difference in the median values of the markers among 
groups. The diagnostic accuracy of proGRP was assessed by plot-
ting receiver operating characteristic (ROC) curves and estimat-
ing the area under the curve (AUC) in discriminating SCLC 
from other conditions. As no definitive diagnostic threshold for 
proGRP has been reported in the Korean population so far, this 
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Fig. 1. Comparison of concentrations of the 3 tumor markers between fresh serum and plasma using Passing-Bablok regression and difference plots in healthy individuals. (A) 
pro-gastrin-releasing peptide (proGRP): slope, 1.32; intercept, 9.62; mean difference, + 18.8. (B) squamous cell cancer antigen (SCC): slope, 1.00; intercept, 0.00; mean 
difference, + 0.1. (C) neuron- specific enolase (NSE): slope, 0.72; intercept, -2.99; mean difference, -5.9.Kim H-R, et al.  •  proGRP Level in Different Types of Specimens and Lung Cancer 
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was calculated by picking the point of the best diagnostic per-
formance on the ROC curve. Test for difference between AUCs 
was done using DeLong’s test for two correlated ROC curve. 
Ethics statement
This study was approved by the Institutional Review Board of 
Chonnam National University Hwasun Hospital (approved num-
ber 2008-75). Informed consent was acquired from all subjects.
RESULTS
Comparison between serum and plasma level
Plasma proGRP was only moderately correlated with serum 
proGRP (r = 0.583, P < 0.01). On average, compared to the se-
rum proGRP levels, the plasma proGRP levels were higher by 
103.3%. In the same samples, plasma SCC was higher than the 
serum SCC level by 15.3%. The serum SCC concentrations were 
significantly better correlated with the plasma SCC (r = 0.905, P < 
0.001) than the serum proGRP was with the plasma proGRP. One 
healthy individual was excluded from the measurement of NSE 
due to insufficient sample volume. The correlation coefficient 
was calculated to be 0.533 between serum and plasma NSE. The 
correlation coefficients between serum and plasma NSE was 
not significantly different from that of serum and plasma proGRP 
(P = 0.729). Contrary to the other 2 markers, NSE was lower in 
plasma than in serum, and the difference was 46.2%. Results of 
the comparison of the tumor markers between serum and plas-
ma are depicted in Fig. 1.
Plasma proGRP in various clinical conditions
At the time of diagnosis, the average plasma proGRP concentra-
Fig. 2. Distribution of plasma proGRP concentrations in healthy individuals, benign 
lung diseases and lung cancer. The average proGRP level in small cell lung cancer 
was higher than those of other conditions except large cell lung cancer which is thought 
to be originated from the neuroendocrine cells. SCLC, small cell lung cancer; NSCLC, 
non-small cell lung cancer. 
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tion of the cancer patients was 336.4 pg/mL and the standard 
deviation was 925.4 pg/mL. Compared to the benign lung dis-
eases (mean, 40.1 pg/mL; standard deviation, 11.5 pg/mL), the 
plasma proGRP level was significantly higher in the lung cancer 
patients. Once the cancer patients were grouped by their histolog-
ical type, the SCLC patients showed the highest level of proGRP 
with a mean of 1,357.5 pg/mL and a standard deviation of 1,698.5 
pg/mL. Large cell lung cancer cases, which along with SCLC is 
thought to originate from neuroendocrine cells, followed next 
showing mean plasma proGRP of 290.9 pg/mL and standard 
deviation of 349.2 pg/mL. Compared to the cases of SCLC and 
large cell, patients diagnosed with adenocarcinoma of the lung, 
squamous cell carcinoma or unspecified NSCLC showed signif-
icantly lower levels of proGRP (P < 0.001, Fig. 2, Table 2).
  Cancer patients with a distant metastasis showed higher lev-
els of plasma proGRP (mean, 5,159.0 pg/mL; standard devia-
tion, 1,247.1 pg/mL) than the patients without metastasis (mean, 
159.6 pg/mL; standard deviation, 404.0 pg/mL, P < 0.05). The 
SCLC patients with an extensive disease had higher proGRP 
(mean, 1,940.1 pg/mL; standard deviation, 1,947.7 pg/mL) than 
the cases with limited disease (mean, 533.0 pg/mL; standard 
deviation, 759.6 pg/mL, P < 0.05).
  Based on the ROC curve analyses, at specificity of 95%, the di-
agnostic sensitivity of plasma proGRP was estimated to be 83.8% 
in distinguishing SCLC from all the other conditions, and 86.5% 
for discriminating SCLC from the nonmalignant cases (Fig. 3). 
DISCUSSION
We investigated the difference of proGRP concentrations in fresh 
serum and plasma. In addition, plasma proGRP levels in vari-
ous benign and malignant lung diseases were compared. Until 
recently, serum was the single recommended sample type of 
proGRP assays. However, poor stability of serum proGRP has 
been a challenging issue (12, 13). According to Yoshimura et al. 
(14), average plasma proGRP concentration was higher than 
Table 2. Plasma proGRP in healthy individuals, benign lung diseases and lung cancer 
patients
Diseases   No.
Mean  
(pg/mL)
Standard 
deviation  
(pg/mL)
Healthy   49   42.5 12.4
Benign diseases   23 40.1 11.5
Lung cancer
   SCLC   37 1,367.5 1,698.5
   NSCLC
      Squmous cell carcinoma
      Adenocarcinoma
      Unspecified NSCLC
      Large cell cancer
      NSCLC total
 
  59
  40
  12
    5
116
 
38.7
59.2
35.2
290.9
56.3
 
12.1
77.1
14.4
349.2
94.6
   Metastatic secondary     2 34.3 n.a.
SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; n.a., not available.Kim H-R, et al.  •  proGRP Level in Different Types of Specimens and Lung Cancer 
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serum by 26% even when tested at a fresh state (14). However, 
another investigation showed there was no difference observed 
between serum and plasma from SCLC patients when assayed 
immediately after collection (15). In this study, we found each 
pair of plasma and serum from a same healthy individual showed 
different proGRP concentration by 103.3% in average, although 
the slope of serum versus plasma was 1.32, Considering there still 
has to be preanalytical steps requiring various period of time, 
the exceptional vulnerability of serum proGRP resulted in the 
seemingly conflicting outcomes from different study settings. 
Also, the low levels of proGRP in healthy individuals seemed to 
contribute to the more pronounced proportional difference be-
tween serum and plasma in our study. 
  A recently introduced automated chemiluminescent immu-
noassay, ARCHITECT ProGRP, recommends plasma as a pre-
ferred specimen. On the contrary, Nordlund et al. (15), preferred 
fresh serum to EDTA plasma, partly because the plasma proGRP 
can be increased by the release of proGRP from thrombocytes 
or leukocytes (15). However, if plasma is separated from the cel-
lular component by simple centrifugation in a timely manner, 
which is quite familiar to most clinical laboratories, spurious 
increase of proGRP in stored plasma specimens may be avoid-
ed. Therefore, plasma is deemed to be the specimen of choice 
for measuring circulating proGRP concentration, given the un-
desirably lowered serum proGRP observed in this study.
  Interestingly, serum and plasma proGRP showed a correla-
tion (r = 0.583) significantly lower than that of SCC but closer to 
that of NSE, in spite of the manufacturer’s option to use either 
type of specimen. Based on the correlation result, the fact that 
some commercially available proGRP assay kits only accepts 
serum proves that additional revision in them is required. 
  As indicated in the previous investigations, circulating proGRP 
levels were significantly higher in the SCLC patients compared 
to the nonmalignant cases or the other types of cancer. Howev-
er, plasma proGRP of the SCLC patients was not statistically sig-
nificantly different compared to large cell lung cancer patients. 
This is partly because only a small number of large cell lung can-
cer patients were included in this study. However, it is also pos-
sible that such a lack of difference was caused by the common 
neuroendocrine origin of both types of cancer. Among NSCLC, 
large cell lung cancer has been known to be closer to SCLC rath-
er than to other types of NSCLC in terms of pathological char-
acteristics. 
  In discriminating SCLC from NSCLC, plasma proGRP showed 
a sensitivity of 51.4% at a specificity of 99%. Against all the be-
nign lung diseases, the diagnostic sensitivity of plasma proGRP 
for detecting SCLC was estimated to be 86.5% at specificity of 
99%. Compared to a previous study (sensitivity 46% and speci-
ficity 96% in the diagnosis of SCLC), the diagnostic performance 
of proGRP revealed in this study was significantly enhanced (5, 
17). We attributed the improved performance of proGRP to the 
use of plasma instead of serum, contrary to the previous clinical 
trials mainly incorporating serum specimens. In addition, the 
diagnostic performance of plasma proGRP for discriminating 
SCLC looked better than other commonly available tumor mark-
ers (18).
  In conclusions, plasma is preferred to serum for measuring a 
circulating level of proGRP. Plasma proGRP concentration mea-
sured by the two-step chemiluminescent immunoassay was 
sensitive and specific for discriminating SCLC from nonmalig-
nant conditions or NSCLC.
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Plasma proGRP Concentration is Sensitive and Specific for Discriminating Small 
Cell Lung Cancer from Nonmalignant Conditions or Non-small Cell Lung Cancer
Hye-Ran Kim, In-Jae Oh, Myung-Geun Shin, Joon-Seok Park, Hyun-Jung Choi, Hee-Jung Ban, Kyu-Sik Kim, Young-Chul Kim,  
Jong-Hee Shin, Dong-Wook Ryang, and Soon-Pal Suh
We compared serum and plasma concentrations of proGRP using fresh specimens, and evaluated the plasma proGRP concentrations 
in benign and malignant conditions including small cell lung carcinoma (SCLC). The plasma concentration is superior to serum level 
for measuring the circulating proGRP. Plasma proGRP concentration measured by the two-step chemiluminescent immunoassay 
was revealed to be a sensitive and specific parameter for discriminating SCLC from nonmalignant conditions or NSCLC.